Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EPS (Weighted Average and Diluted) (2022 - 2025)

PAVmed has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$5.52 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$5.52 for Q4 2025, down 139.12% from a year ago — trailing twelve months through Dec 2025 was -$6.21 (down 174.19% YoY), and the annual figure for FY2025 was -$5.63, down 137.79%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$5.52 at PAVmed, down from -$0.29 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PAVM hit a ceiling of $14.11 in Q4 2024 and a floor of -$14.25 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$1.56 (2023), compared with a mean of -$1.42.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 720.69% in 2023 and later skyrocketed 831.09% in 2024.
  • PAVmed's EPS (Weighted Average and Diluted) stood at -$14.25 in 2022, then soared by 86.46% to -$1.93 in 2023, then skyrocketed by 831.09% to $14.11 in 2024, then plummeted by 139.12% to -$5.52 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$5.52 (Q4 2025), -$0.29 (Q3 2025), and -$0.74 (Q2 2025) per Business Quant data.